Immuron Limited (IMRN): Bathi resik saben saham sajrone 12 wulan pungkasan

Immuron Limited relies on an efficient outsourcing scheme for international logistics to minimize operational risks. The company's annual revenue per unit reflects the earnings per share trend, while -0.34 indicates the current level. Growth is driven by Travelan sales and the over-the-counter segment, with a scientific foundation based on innovative colostrum-derived antibodies to combat gastrointestinal infections.

IMRN (Immuron Limited) riwayat Bathi resik saben saham sajrone patang kuartal pungkasan saka 04.07.2022 nganti 10.11.2026

IMRN (Immuron Ltd): rincian analitis lan laporan miturut indikator

- rega saham lan target rega konsensus:

Rega saham Immuron Inc|IMRN - Target median analis

- data kapitalisasi bursa:

Biji pasar Immuron Limited|IMRN - Total Nilai Bisnis

- indikator nilai aset resik miturut neraca:

Nilai Buku saben Saham Immuron|IMRN - Pambiji Buku Bisnis|Rasio Nilai Pasar marang Nilai Buku immuron.com.au|IMRN - Gunggung Aset Perusahaan

- rincian struktur utang lan likuiditas bisnis:

Utang marang Ekuitas Immuron Limited|IMRN - Rasio utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas Immuron Inc|IMRN - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku Immuron Limited|IMRN - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Immuron|Likuiditas cepet immuron.com.au

- indikator pendapatan resik lan kelipatan nilai:

IMRN - Bathi perusahaan|Bathi mangsa ngarep Immuron Limited|IMRN - Nilai perusahaan marang bathi resik|Rega marang bathi mangsa ngarep Immuron Inc|IMRN - Rasio rega marang bathi tumrap wutah|Pangali EV/EBITDA Immuron Limited|IMRN - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Immuron|IMRN - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan immuron.com.au|IMRN - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep Immuron Limited

Analisis kabeh metrik perusahaan:IMRN - immuron.com.au

Investors assess the issuer's financial stability through the lens of actual earnings per share. This indicator aggregates net income over four quarters, dividing it by the total number of shares to identify true profitability. For the biotech firm Immuron Limited (IMRN), which invests in immunologists and vaccines, this metric reflects the efficiency of its capital burn. By analyzing the rolling net income per share trend on GURU.Markets, one can uncover hidden write-offs.

Perusahaan pesaing